Vir Biotechnology has dosed the first patient in one of three expansion cohorts in its ongoing Phase I clinical trial of VIR-5500 for metastatic prostate cancer.
The study is assessing the safety and efficacy of VIR-5500, a prostate-specific membrane antigen (PSMA)-targeted, PRO-XTEN dual-masked T-cell engager, as a monotherapy in late-line metastatic castration-resistant prostate cancer (mCRPC).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It is also evaluating VIR-5500 in combination with an androgen receptor pathway inhibitor (ARPI) in early-line mCRPC and metastatic hormone-sensitive prostate cancer (mHSPC).
The first monotherapy expansion cohort in late-line mCRPC has started enrolment based on favourable safety and preliminary anti-tumour activity demonstrated in monotherapy dose-escalation data.
Presented at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in February, these results led to the selection of a step-up dosing regimen of Q3W 800/2000/3500 µg/kg for the expansion cohort.
This stage will measure safety and efficacy endpoints, including Prostate-Specific Antigen response rate and objective response rate.
It will enrol patients with mCRPC who are refractory following multiple prior lines of therapy, including at least one second-generation androgen receptor pathway inhibitor and one taxane regimen, as well as standard-of-care radioligand-based therapy.
Dose-escalation of VIR-5500 in combination with enzalutamide continues in early-line mCRPC. Future combination dose-expansion cohorts are planned for early-line mCRPC and mHSPC, with pivotal Phase III trials anticipated in 2027.
VIR-5500, a bispecific PSMA and CD3 binding T-cell engager utilising PRO-XTEN masking technology, remains under investigation in this open-label, non-randomised Phase I trial.
Vir Biotechnology CEO Marianne De Backer said: “The initiation of the VIR-5500 expansion cohorts underscores the significant momentum behind this programme and the enthusiasm we are seeing across the clinical community.
“We are encouraged by the promising anti-tumour activity shown in the Phase I data announced earlier this year and look forward to collaborating with Astellas after closing of the transaction to explore VIR-5500’s potential to make a meaningful difference across the spectrum of metastatic prostate cancer.”
In July 2025, Vir Biotechnology dosed the first subject in the non-randomised Phase I trial to assess VIR-5525, the investigational dual-masked T-cell engager (TCE) that targets epidermal growth factor receptor (EGFR).
